The impact of aspirin use on outcomes in patients with inflammatory bowel disease: Insights from a national database.

Autor: Iqbal H; Department of Internal Medicine, University of California San Francisco, Fresno, USA. Humzah.Iqbal@ucsf.edu., Arora GS; Department of Internal Medicine, University of California Riverside, Riverside, USA., Singh I; Dayanand Medical College and Hospital, Ludhiana, India., Kohli I; Icahn School of Medicine at Mount Sinai, New York City, USA., Chaudhry H; Department of Internal Medicine, University of California San Francisco, Fresno, USA., Sohal A; Liver Institute Northwest, Seattle, USA., Prajapati D; Department of Gastroenterology and Hepatology, University of California San Francisco, Fresno, USA.
Jazyk: angličtina
Zdroj: International journal of colorectal disease [Int J Colorectal Dis] 2023 Dec 20; Vol. 39 (1), pp. 6. Date of Electronic Publication: 2023 Dec 20.
DOI: 10.1007/s00384-023-04575-7
Abstrakt: Background: Inflammatory bowel disease (IBD) is an inflammatory disorder that can increase the risk of mortality. Aspirin is an anti-inflammatory drug used for primary prevention of cardiovascular events. A single center analysis previously reported that aspirin use did not impact major outcomes in IBD. In this study, we aim to assess the impact of aspirin use on mortality and other outcomes in patients with IBD using national data.
Methods: National inpatient sample (NIS) 2016-2020 was used to identify adult patients with IBD. Data were collected on patient demographics, hospital characteristics, and comorbidities. The outcomes studied were in-hospital mortality, sepsis, shock, Intensive Care Unit (ICU) admission, and need for surgery. Multivariate logistic regression analysis was performed.
Results: A total of 1,524,820 IBD hospitalizations were included. Of these, 137,430 (9%) were long-term aspirin users. The majority of the patients in the aspirin group were aged > 65 years (34.11%), female (56.37%), White (78.83%) and had Medicare insurance (36.77%). Aspirin users had a lower incidence of in-hospital mortality (1.6% vs 1.4%, P = 0.06), sepsis (2.5% vs 2.9%, P < 0.001), shock (2.9% vs 3.4%, P < 0.001), ICU admission (2.6% vs 2.9%, P < 0.001), need for surgery (2.1% vs 4.2%, P < 0.001). After adjusting for confounders, aspirin was associated with a reduction in mortality (adjusted odds ratio: 0.49, 95%CI 0.45-0.55, P < 0.001).
Conclusion: Our study reports that aspirin use among patients with IBD was associated with a lower risk of death, sepsis, and shock. Aspirin use may have a protective effect in patients with IBD. Further studies are needed to confirm these results.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: